Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, Mantle-Cell 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 30fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 18Tacrolimus 17Mycophenolic Acid 16Methotrexate 16Whole-Body Irradiation 14Etoposide 13Vincristine 12Doxorubicin 12Dexamethasone 11Busulfan 11Cytarabine 10Antilymphocyte Serum 10venetoclax 9Prednisone 9nelarabine 8Rituximab 8Filgrastim 8Cyclosporine 8Calcium Dobesilate 8merphos 7Melphalan 7Radiotherapy 6prednylidene 5deltacortene 5Methylprednisolone 5Azacitidine 5Sirolimus 4Granulocyte Colony-Stimulating Factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Hyaluronoglucosaminidase × Clear all
NCT05289687 2026-05-05

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Eastern Cooperative Oncology Group

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡